KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Petmed Express (PETS) EBIT (2016 - 2025)

Petmed Express' EBIT history spans 16 years, with the latest figure at -$10.5 million for Q4 2025.

  • For Q4 2025, EBIT fell 2226.44% year-over-year to -$10.5 million; the TTM value through Dec 2025 reached -$59.0 million, down 9107.79%, while the annual FY2025 figure was -$1.5 million, 81.25% up from the prior year.
  • EBIT reached -$10.5 million in Q4 2025 per PETS's latest filing, down from -$8.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $8.4 million in Q1 2021 to a low of -$34.1 million in Q2 2025.
  • Average EBIT over 5 years is -$1.1 million, with a median of $171000.0 recorded in 2023.
  • Peak YoY movement for EBIT: soared 306.11% in 2024, then tumbled 2226.44% in 2025.
  • A 5-year view of EBIT shows it stood at $5.1 million in 2021, then crashed by 114.94% to -$769000.0 in 2022, then crashed by 299.74% to -$3.1 million in 2023, then skyrocketed by 85.36% to -$450000.0 in 2024, then crashed by 2226.44% to -$10.5 million in 2025.
  • Per Business Quant, the three most recent readings for PETS's EBIT are -$10.5 million (Q4 2025), -$8.4 million (Q3 2025), and -$34.1 million (Q2 2025).